Patents Examined by Garnette D. Draper
  • Human interleukin-5 receptor
    Patent number: 5807991
    Abstract: The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5 receptor and products including murine interleukin 5 receptor, murine secretory interleukin 5 receptor, and human interleukin 5 receptor which are produced using the isolated cDNA sequence. These products may be useful for a therapeutic agent for autoimmune disorders and diseases with eosinophilia in which human IL-5 is believed to be involved.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: September 15, 1998
    Assignee: Kiyoshi Takatsu
    Inventors: Kiyoshi Takatsu, Akira Tominaga, Satoshi Takagi, Yoshiyuki Murata
  • Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
    Patent number: 5783181
    Abstract: A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 21, 1998
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Michael Joseph Browne, Peter Ronald Young, Allan Richard Shatzman, Kay Elizabeth Murphy, Conrad Gerald Chapman, Helen Elizabeth Clinkenbeard
  • DNA encoding type-I interleukin-I receptor-like protein designated 2F1
    Patent number: 5776731
    Abstract: 2F1 polypeptides members of the IL-1 receptor family are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: July 7, 1998
    Assignee: Immunex Corporation
    Inventors: Patricia Parnet, John E. Sims
  • Tumor necrosis factor muteins
    Patent number: 5773582
    Abstract: Muteins of human tumor necrosis factor (hTNF), a process for production thereof, and DNAs encoding these muteins are found to have a superior antitumor activity and lower acute lethal toxicity compared to the wild-type human tumor necrosis factor.
    Type: Grant
    Filed: October 4, 1995
    Date of Patent: June 30, 1998
    Assignee: Hanil Synthetic Fiber Co., Ltd.
    Inventors: Hang-Cheol Shin, Nam-Kyu Shin, Inkyung Lee, Sungzong Kang
  • Use of interleukin-4 receptors to inhibit biological responses mediated by interleukin-4
    Patent number: 5767065
    Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 16, 1998
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • DNA encoding murine interleukin-5 receptor
    Patent number: 5760204
    Abstract: The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5 receptor and products including murine interleukin 5 receptor, murine secretory interleukin 5 receptor, and human interleukin 5 receptor which are produced using the isolated cDNA sequence. These products may be useful for a therapeutic agent for autoimmune disorders and diseases with eosinophilia in which human IL-5 is believed to be involved.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: June 2, 1998
    Assignee: Kiyoshi Takatsu
    Inventors: Kiyoshi Takatsu, Akira Tominaga, Satoshi Takagi
  • Method of treating graft-versus-host disease
    Patent number: 5747444
    Abstract: Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 5, 1998
    Assignee: Chiron Corporation
    Inventors: John Stephen Haskill, Peter Ralph
  • Calcineurin inhibitory compounds and anchoring protein to induce IL-2 gene expression
    Patent number: 5744354
    Abstract: The present invention provides compositions and methods useful for isolating calcineurin as well as inhibiting calcineurin activity. The compositions are peptides that contain regions that are homologous to calcineurin-binding regions of AKAP 79. Also provided are methods for determining if a cell contains a calcineurin-binding and PKA-binding anchoring protein that are useful for identifying additional proteins that bind both calcineurin and PKA. Another aspect of the present invention is methods for enhancing expression of interleukin 2 by T cells.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: April 28, 1998
    Assignees: ICOS Corporation, The State of Oregon, acting by and through the Oregon State Board of Higher Education, and on behalf of Oregon Health Sciences University
    Inventors: Robert Owen Lockerbie, John D. Scott, Vincent M. Coghlan, Monique L. Howard, W. Michael Gallatin
  • Method of treating metabolic bone diseases with an IL-1 receptor
    Patent number: 5726148
    Abstract: A method of treating metabolic bone diseases comprising using a pharmaceutical composition which comprises as an active ingredient IL-1 receptor, a soluble fragment consisting of an extracellular domain of IL-1R or a fragment thereof derived from mammals. The composition has a bone resorption inhibiting activity and is useful for the therapy and prophylaxis of metabolic bone diseases.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 10, 1998
    Assignee: Hoechst Japan Limited
    Inventors: Masakazu Katoh, Kazuyuki Kitamura
  • Method for enhancing wound healing/repair with IL-4
    Patent number: 5723119
    Abstract: Disclosed are methods of enhancing the reparative phase of wound healing and repair in a mammal by administering to the wound site during the reparative phase an effective amount of IL-4. Also disclosed are methods of enhancing the healing and repair of infected wounds, wounds of diabetic mammals, and wounds of immunocompromised mammals by administering a therapeutically effective amount of IL-4 to the wound.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: March 3, 1998
    Assignee: Schering Corporation
    Inventors: Martin A. Schwarz, Lee M. Sullivan, Loretta A. Bober, Michael J. Grace
  • Methods of use of IL-1.alpha.
    Patent number: 5702698
    Abstract: Methods are disclosed for promoting production of colony stimulating factor and inhibiting growth of Meth A tumor cells comprising administering a pharmaceutically effective amount of modified IL-1.alpha. to a subject.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 30, 1997
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Satoru Nakai, Mayumi Kaneta, Yoshikazu Kikumoto, Yeong-Man Hong, Kazuyoshi Kawai, Setsuko Takegata, Kiyoshi Ishii, Yasuo Yanagihara, Yoshikatsu Hirai
  • DNA that encodes a tumor necrosis factor inhibitory protein and a recombinant method of production
    Patent number: 5695953
    Abstract: Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified and the DNA that encodes the TNF inhibitory protein, vectors, host cells, and a recombinant method for producing the encoded protein are also set forth. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF.
    Type: Grant
    Filed: April 30, 1992
    Date of Patent: December 9, 1997
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Hartmut Engelmann, Dan Aderka, Menachem Rubinstein
  • Mutant interleukin 6 with improved biological activity over wild interleukin 6
    Patent number: 5681723
    Abstract: The present invention is drawn to mutant interleukin 6, which has the amino acid arginine in position 176, replacing serine in position 176 with wild-type interleukin 6. The mutant interleukin 6 of the present invention has greater biological activity than the wild-type protein. The present invention is further drawn to methods of making mutant interleukin 6, having arginine at position 176 and methods of using the same.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: October 28, 1997
    Assignee: Instituto di Ricerche di Biologia Molecolare P. Angelett S.P.A.
    Inventors: Gennaro Ciliberto, Rocco Savino
  • Brain endothelial cell protein induced by nerve growth factor
    Patent number: 5677277
    Abstract: The present invention provides a novel isolated and purified protein that is produced by brain endothelial cells, has a molecular weight of approximately 67 kDa of SDS-PAGE, with the protein being capable of stimulating proliferation of cerebral arteriole smooth muscle cells. Also provided are various methods of using this novel protein or the gene encoding this protein, including methods of treating various cerebrovascular diseases.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: October 14, 1997
    Assignee: Research Development Foundation
    Inventors: Frank M. Yatsu, Nargis A. Alam, Syed S. Alam
  • Method of purifying keratinocyte growth factor (KGF)
    Patent number: 5665870
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: September 9, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey S. Rubin, Paul W. Finch, Stuart A. Aaronson
  • Neutrophil chemotactic factor
    Patent number: 5652338
    Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.
    Type: Grant
    Filed: March 16, 1988
    Date of Patent: July 29, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
  • Modified tumor cytotoxic factor (TCF) and DNA encoding such
    Patent number: 5648233
    Abstract: Modified TCF in which one or more amino-acid residues of the wild type TCF responsible for glycosylation are substituted or deleted so that at least one N-linked oligosaccharide chain is removed. The modified TCFs have a longer biological half-lives without loss of their biological activities. The modified TCFs are therapeutically important as agents for liver diseases or as anti-cancer drugs.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: July 15, 1997
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Kyoji Yamaguchi, Nobuyuki Shima, Akihiko Murakami, Masaaki Goto, Eisuke Tsuda, Hiroaki Masunaga, Reiko Takahira, Fumiko Oogaki, Masatsugu Ueda, Kanji Higashio
  • Methods of modulating fibronectin extracellular matrix assembly
    Patent number: 5629291
    Abstract: The present invention provides fibronectin self-assembly sites. The invention provides a set of polypeptides derived from the first type III repeat of fibronectin which contain a fibronectin-fibronectin binding site. These polypeptides have been used to obtain a second set of polypeptides derived from the C-terminal type I repeats which contain a second fibronectin-fibronectin binding site which interacts with the first type III repeat of fibronectin. These polypeptides are capable of inhibiting fibronectin matrix assembly by interfering with fibronectin-fibronectin binding. These polypeptides are also capable of enhancing fibronectin matrix assembly and inducing disulfide cross-linking of fibronectin molecules in vitro. In addition, these polypeptides are capable of inhibiting migration of tumor cells. The polypeptides of the present invention have a number of related uses as well.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: May 13, 1997
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Alex Morla
  • Erythropoietin binding protein from mammalian serum
    Patent number: 5625035
    Abstract: Purified mammalian erythropoietin binding-protein is disclosed, and its isolation, identification, characterization, purification, and immunoassay are described. The erythropoietin binding protein can be used for regulation of erythropoiesis by regulating levels and half-life of erythropoietin. A diagnostic kit for determination of level of erythropoietin binding protein is also described.
    Type: Grant
    Filed: February 23, 1994
    Date of Patent: April 29, 1997
    Assignee: The Regents, University of California
    Inventor: Gisela K. Clemons
  • Synthesis of peptides as cloned ubiquitin extensions
    Patent number: 5620923
    Abstract: A method for the preparation of synthetic peptide products containing up to about forty amino acid residues as ubiquitin-carboxyl terminal extensions expressed in procaryotic cells such as E. coli is disclosed. This is accomplished by cloning appropriate oligonucleotides encoding the desired peptide as a ubiquitin peptide extension gene, splicing the gene into an appropriate plasmid which, in turn is transformed into E. coli, or other appropriate procaryotic cells and inducing expression of the ubiquitin peptide fusion product. When expressed, the cells produce recoverable amounts of ubiquitin extended at its carboxyl terminus by the encoded carboxyl terminal extended peptide (CTEP). The peptide can be recovered as ubiquitin fused extension products (Ub-CTEP) or, alternatively, can be cleaved from the ubiquitin by an appropriate eucaryotic peptidase and purified.
    Type: Grant
    Filed: April 3, 1992
    Date of Patent: April 15, 1997
    Assignee: The University of Utah
    Inventors: Martin C. Rechsteiner, Yung Yoo, Keith D. Wilkinson, Kevin V. Rote